Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHEARLESS: BMN 307 in PKU
NCT04480567Phase 2Active, not recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
A Phase 2 trial of Domofenogene zalfaparvovec in phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical. Started Sep 2020; status: active, not recruiting.
02
Drugs
Domofenogene zalfaparvovec
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT04480567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480567.